Welcome to our dedicated page for GENELUX SEC filings (Ticker: GNLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genelux Corporation filings document the regulatory record for a clinical-stage oncology issuer developing Olvi-Vec and related immuno-oncology programs. Its disclosures include proxy statements for director elections, auditor ratification and annual meeting governance, as well as Form 8-K reports covering material agreements, Regulation FD presentations, equity financing arrangements and capital-structure updates.
The filing record also covers shelf registration and prospectus supplement activity for common stock offerings, use-of-proceeds disclosures for research and development and clinical trial expenses, and compensation matters such as outstanding option exercise-price reductions under equity incentive plans.
GENELUX Corp (GNLX) reported that Chief Technical Officer Joseph Cappello sold 10,257 shares of common stock on August 31, 2026 at a weighted average price of $2.7408 per share, with prices ranging from $2.70 to $2.78. The shares were sold to cover estimated taxes arising from the vesting of restricted stock units, and he held 318,480 shares directly afterward. No Rule 10b5-1 trading plan is reported for this transaction.
GENELUX Corp (GNLX) reported that President and CEO Thomas Zindrick sold 34,463 shares of common stock on August 31, 2026 at a weighted average price of $2.6666 per share, in transactions with prices between $2.59 and $2.81. The company states these shares were sold to cover the reporting person's estimated taxes related to the vesting of restricted stock units. Following the sale, Zindrick directly holds 1,226,427 shares of GENELUX common stock, and no Rule 10b5-1 trading plan is reported for this transaction.
GENELUX Corp (GNLX) reported that Chief Scientific Officer Yong Yu sold 9,683 shares of common stock on August 31, 2026 at a weighted average price of $2.7531 per share in an open-market or private transaction. According to the company’s disclosure, these shares were sold to cover estimated taxes arising from the vesting of restricted stock units. After this tax-related sale, Yu directly holds 258,688 shares of GENELUX common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Genelux Corporation, a late clinical-stage oncology biotech, reported no revenue and a larger net loss as it advances its lead oncolytic virus candidate Olvi-Vec. Net loss was $9.5 million for the quarter and $18.4 million for the first half of 2026, driven mainly by higher research and development spending.
R&D expenses rose to $12.3 million for the six months, largely from the Phase 3 On Prime/GOG-3076 registration trial, while general and administrative costs were $6.5 million. Cash, cash equivalents, restricted cash and marketable securities totaled $18.7 million at June 30, 2026, after a $18.5 million underwritten equity offering and modest ATM sales.
The company discloses substantial doubt about its ability to continue as a going concern, given recurring losses and cash used in operations of $12.5 million in the first half. Management currently expects existing funds to support planned operations into the first quarter of 2027 and anticipates needing additional financing to complete development and potential commercialization of Olvi-Vec.
GENELUX Corp Chief Scientific Officer Yong Yu reported selling 653 shares of common stock on August 4, 2026, at a weighted average price of $2.9434 per share, in a sale described as open-market or private. A footnote states the shares were sold to cover estimated taxes from the vesting of restricted stock units, and Yu held 268,371 shares afterward.
Genelux Corp reports that its Chief Technical Officer, Joseph Cappello, sold 653 shares of common stock on 2026-08-04 at a weighted average price of $2.9467 per share, within a $2.91 to $2.97 range, to cover estimated taxes from vesting restricted stock units; he now holds 328,737 shares directly.
Zindrick Thomas, President and CEO of Genelux Corp, reported selling 3,023 shares of Common Stock on August 4, 2026. The shares were sold at a weighted average price of $2.9459 per share, in a range between $2.905 and $2.97, to cover estimated taxes related to the vesting of restricted stock units. After these tax-related sales, he directly holds 1,260,890 shares of Genelux common stock.
GENELUX Corp director John W. Smither reported selling 12,000 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $2.9082 per share to cover estimated taxes related to the vesting of restricted stock units. After this tax-related sale, Smither directly holds 91,403 shares of GENELUX common stock.
Genelux Corporation reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. As of the April 17, 2026 record date, 44,842,243 common shares were outstanding and entitled to vote, and 28,263,200 shares were represented in person, virtually or by proxy, about 63.03% of those eligible.
Stockholders elected Class I director John Smither to serve until the 2029 Annual Meeting, with 8,696,891 votes for, 3,393,408 withheld, and 16,172,901 broker non-votes. They also ratified Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,092,768 votes for, 105,158 against, 65,274 abstentions, and no broker non-votes.